Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P568: The impact of a virtual clinic on clinical decision-making and healthcare resource use vs. standard care: The Oxford experienceECCO '18 Vienna
Year: 2018
Authors:

M. FitzPatrick*, T. Ambrose, L. Thomas, S. Cullen, G. Blackburn, K. Davies, S. Travis, S. Keshav, A. Walsh, R. Palmer, S. Cripps, O. Brain

Translational Gastroenterology Unit, Oxford, UK

P569: Outcomes of IBD patients treated with infliximab: The impact of therapeutic drug monitoring in real-life clinical practiceECCO '18 Vienna
Year: 2018
Authors:

N. Kamperidis, P. Middleton, T. Tyrrell, I. Stasinos, N. Arebi

St Mark's Hospital, London, UK

P570: Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: Results from GEMINI trial dataECCO '18 Vienna
Year: 2018
Authors:

D.T. Rubin1, D. Tudor2, J.M. Khalid3, H. Patel3*

1University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA, 2Takeda Pharmaceuticals International AG, Zurich, Switzerland, 3Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

P571: Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)ECCO '18 Vienna
Year: 2018
Authors:

S.S.R. Pulusu1*, A. Srinivasan2, K. Krishnaprasad3, D. Cheng4, T. Mogilevski5, E. Flanagan6, C. Keung7, C. Wu8, R. Prosser9, E. Sawyer10, Q.-U.-A. Rizvi11, H. Su12, W.-K. Leung13, A. Edmundson3, S. Cooke14, G. Mahy14, L. Thin15, G. Radford-Smith16, M. Sparrow12, J.M. Andrews11, S. Connor10, P. Bampton17, S. Ghaly8, D. Van Langenberg7, S. Bell6, P. De Cruz5, J. Begun4, S. Ng18, S. Travis2, I. Lawrance1

1St John of God, Subiaco, IBD Center, Perth, Australia, 2Oxford University Hospitals, Oxford, UK, 3QIMR Berghofer Medical Research Institute, Brisbane, Australia, 4Mater Hospital, Brisbane, Australia, 5Austin Health, Melbourne, Australia, 6St Vincents Hospital, Melbourne, Australia, 7Eastern Health, Melbourne, Australia, 8St Vincents Hospital, Sydney, Australia, 9Flinders Medical centre, Adelaide, Australia, 10Liverpool Hospital, Sydney, Australia, 11Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, 12The Alfred Hospital, Melbourne, Australia, 13The Chinese University of Hong Kong, Hong Kong, Hong Kong, 14Townsville Hospital, Townsville, Australia, 15Fiona Stanley Hospital, Perth, Australia, 16QIMR Berghofer Medical Research Institute, Brisbane, Australia, 17Flinders Medical Centre, Adelaide, Australia, 18The Chinese University of Hong Kong, Honk kong, Hong Kong

P572: Reactive dose escalation of infliximab in patients with Crohn’s disease in TAILORIX leads to improved outcomesECCO '18 Vienna
Year: 2018
Authors:

E. Dreesen1*, D. Laharie2, G. Lambrecht3, P. Bossuyt4, A. Buisson5, J. Filippi6, P. Van Hootegem7, G. D'Haens8, S. Vermeire9,10, A. Gils1

1KU Leuven, Departement of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2Hospital Haut-Lévêque, Bordeaux, France, 3Damiaan Hospital, Oostende, Belgium, 4Imelda Hospital, Bonheiden, Belgium, 5Hospital Estaing, Clermont-Ferrand, France, 6Hospital Archet, Nice, France, 7Sint-Lucas Hospital, Brugge, Belgium, 8Academic Medical Centre, Amsterdam, The Netherlands, 9University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 10KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P573: Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteersECCO '18 Vienna
Year: 2018
Authors:

L. Peyrin-Biroulet1, J. Adams2, S. Turner2, L. Trokan2, J. Panes3*

1Lorraine University, Department of Gastroenterology and Inserm U954, Nancy, France, 2Arena Pharmaceuticals, Inc., San Diego, USA, 3Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

P574: The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trialECCO '18 Vienna
Year: 2018
Authors:

G. D'Haens1*, Z. Cabrijan2, M. Eberhardson3, R. van den Bergh1, M. Löwenberg1, G. Fiorino4, S. Danese4, Y. Levine5, D. Chernoff5

1Academic Medical Center (AMC) University of Amsterdam, Amsterdam, The Netherlands, 2School of Medicine, University of Osijek, Osijek, Croatia, 3Karolinska Institute, Stockholm, Sweden, 4Humanitas Clinical Institute, Milan, Italy, 5SetPoint Medical, Inc., Valencia, USA

P575: Vedolizumab trough levels predict clinical outcomes in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

L. Guidi1*, D. Pugliese1, T. Panici Tonucci1, B. Tolusso2, C. Felice1, C. Di Mario2, A. Papa1, E. Gremese2, A. Gasbarrini3, G.L. Rapaccini1, A. Armuzzi1

1Fondazione Policlinico A. Gemelli, Catholic University, Internal Medicine and Gastroenterology Unit, Presidio Columbus, Rome, Italy, 2Fondazione Policlinico A. Gemelli, Catholic University, Rheumatology Unit, Presidio Columbus, Rome, Italy, 3Fondazione Policlinico A. Gemelli, Catholic University, Internal Medicine and Gastroenterology Unit, Rome, Italy

P576: Impact of improved access to biologic therapies and physician engagement on excess steroid exposure: Results from a UK audit of 3561 patientsECCO '18 Vienna
Year: 2018
Authors:

C. Selinger1, G.C. Parkes2*, M. Adamson3, A. Bassi4, F. Donovan5, A. Fraser6, B. George7, L. Grey8, V. Hall9, J. Lindi10, H. Ludlow11, I. Parisi12, P. Patel13, R. Pollock14, S. Salunke15, J. Saunders16, G. Scott17, M. Smith18, T. Raine19

1Leeds Teaching Hospitals, Leeds, UK, 2Royal London Hospital, Barts Health, London, UK, 3Salisbury NHS Foundation Trust, Salisbury, UK, 4St Helens and Knowsley Foundation Trust, St Helens, UK, 5Kingston Hospital NHS Foundation Trust, Kingston upon Thames, UK, 6Bristol Royal Infirmary, Bristol, UK, 7Torbay and South Devon NHS Trust, Torbay, UK, 8Wirral University Teaching Hospital, Birkenhead, UK, 9Royal Bolton Hospital, Bolton, UK, 10North Manchester General Hospital, Manchester, UK, 11University Hospital Llandough, Cardiff, UK, 12University College London Hospitals, London, UK, 13Epsom and St Helier University Hospitals NHS Trust, Epsom, UK, 14St George's University Hospitals NHS Foundation Trust, London, UK, 15Forth Valley Royal Hospital, Larbert, UK, 16Royal United Hospitals Bath NHS Foundation Trust, Bath, UK, 17East Kent Hospitals University NHS Foundation Trust, Margate, UK, 18Brighton and Sussex University Hospitals NHS Trust, Brighton, UK, 19Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

P577: A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Orlando1*, F.S. Macaluso1, W. Fries2, A.C. Privitera3, M. Cappello4, S. Siringo5, G. Inserra6, A. Magnano7, R. Di Mitri8, N. Belluardo9, G. Scarpulla10, G. Magrì11, N. Trovatello12, A. Carroccio13, S. Genova14, C. Bertolami15, R. Vassallo16, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

1Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo, Italy, 2Inflammatory Bowel Disease Unit, A.O.U. Policlinico "G. Martino”, Messina, Italy, 3IBD Unit, A.O. "Cannizzaro”, Catania, Italy, 4Gastroenterology and Hepatology Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy, 5Gastroenterology Unit, A.R.N.A.S. “Garibaldi”, Catania, Italy, 6Internal Medicine Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy, 7Gastroenterology Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy, 8Gastroenterology and Endoscopy Unit, A.R.N.A.S. “Civico Di Cristina Benfratelli”, Palermo, Italy, 9Gastroenterology Unit, A.O. “Guzzardi”, Vittoria, Italy, 10Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, Italy, 11Gastroenterology Unit, A.O. “Santa Marta e S. Venera”, Acireale, Italy, 12Surgery Unit, A.O. “Umberto I”, Siracusa, Italy, 13Internal Medicine Unit, A.O. “Giovanni Paolo II”, Sciacca, Italy, 14Gastroenterology and Endoscopy Unit, A.O. “S. Antonio Abate”, Trapani, Italy, 15Gastroenterology Unit, A.O.O.R. “Papardo Piemonte”, Messina, Italy, Messina, Italy, 16Gastroenterology and Endoscopy Unit, A.O. “Buccheri La Ferla Fatebenefratelli”, Palermo, Italy

P578: Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort seriesECCO '18 Vienna
Year: 2018
Authors:

M.E. Stellingwerf1*, S. Sahami1, D.C. Winter2, H.E. Mulcahy2, G. Doherty2, G. Cullen2, S. Martin2, G.R. D'Haens3, W.A. Bemelman1, C.J. Buskens1

1Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands, 2St Vincent's University Hospital, Department of Colorectal Disease, Dublin, Ireland, 3Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands

P579: Risk of CMV reactivation in UC patients with previous history of CMV infection following infliximab or vedolizumab treatmentsECCO '18 Vienna
Year: 2018
Authors:

C. Hommel1*, X. Roblin2,3, L. Brichet2,3, B. Bihin4, S. Pillet3,5, J.-F. Rahier1

1CHU UCL Namur, Catholic University of Louvain, Gastroenterology and Hepatology, Yvoir, Belgium, 2University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 3Faculty of Medicine of Saint-Etienne, University of Lyon, EA-3064, Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Lyon, France, 4CHU UCL Namur, Scientific Support Unit, Yvoir, Belgium, 5University of Saint Etienne, Laboratory of Infectious Agents and Hygiene, Saint Etienne, France

P580: Vitamin D substitution dose in IBD patients: Higher than recommended?ECCO '18 Vienna
Year: 2018
Authors:

V. Kojecky1*, J. Matous2, Z. Zadorova3, P. Kohout4

1Bata Regional Hospital, Internal Clinic, Zlin, Czech Republic, 2Third Faculty of Medicine, Charles University in Prague, 2nd Department of Internal Medicine, Prague, Czech Republic, 3Third Faculty of Medicine, Charles University in Prague, 2nd Department of Internal Medicine, Prague, Czech Republic, 4Thomayer Hospital, 2nd Department of Internal Medicine, Prague, Czech Republic

P581: Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohortECCO '18 Vienna
Year: 2018
Authors:

V. Pittet1*, N. Aslan2, N. Fournier1, A. Decollogny1, A. Schoepfer2, F. Seibold3, P.-Y. Rodondi4

1Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 2Lausanne University Hospital, Department of Gastroenterology and Hepatology, Lausanne, Switzerland, 3Lindenhof Spital, Division of Gastroenterology, Bern, Switzerland, 4Institute of Social and Preventive Medicine, Centre for Integrative and Complementary Medicines, Lausanne, Switzerland

P582: Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohortECCO '18 Vienna
Year: 2018
Authors:

J. Doherty*, M. Buckley, G. Cullen, G. Horgan, H. Mulcahy, G. Doherty, J. Sheridan

St Vincents University Hospital and School of Medicine, University College Dublin, Centre for Colorectal Disease, Dublin 4, Ireland

P583: Efficacy of vedolizumab (VDZ) by disease extension in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

P. Michetti1*, F. Braegger2, C. Kempf2, M. Allez3

1Gastro-entérologie La Source-Beaulieu and Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, Crohn and Colitis Center, Lausanne, Switzerland, 2Takeda Pharmaceuticals International AG, Zurich, Switzerland, 3Hôpital Saint-Louis, APHP, INSERM UMRS 1160, Université Denis Diderot, Gastroenterology and Hepatology, Paris, France

P584: Rare and severe complications in children with paediatric-onset IBD; the international PIBD SETQuality Safety Registry by PIBDnetECCO '18 Vienna
Year: 2018
Authors:

M. Aardoom1*, P. Kemos2, F. Ruemmele3, N. Croft2, L. de Ridder1, on behalf of the PIBD SETQuality consortium and PIBDnet

1Erasmus MC, Sophia Children's Hospital, Paediatric Gastroenterology, Rotterdam, The Netherlands, 2Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, Paediatric Gastroenterology, London, UK, 3Université Paris Descartes, Sorbonne Paris Cité, APHP, Hopital Necker Enfants Malades, Department of Paediatric Gastroenterology, Paris, France

P585: Impact of timing of thiopurine treatment on first intestinal resection in Crohn’s disease with poor prognostic factors: A nationwide population-based cohort study 2004–2015ECCO '18 Vienna
Year: 2018
Authors:

S.Y. Shin1*, J. Lee2, J.J. Park1, J.H. Cheon3, T.I. Kim3, H. Park1, W.H. Kim3, A.S. Shin2

1Gangnam Severance Hospital, Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea, 2Seoul National University College of Medicine, Preventive Medicine, Seoul, South Korea, 3Severance Hospital, Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea

P586: Tofacitinib for the induction and maintenance of medically resistant ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

R. Weisshof*, M. Aharoni Golan, D.T. Rubin

University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, USA

P587: Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case seriesECCO '18 Vienna
Year: 2018
Authors:

V. Biemans1,2*, C. van der Woude3, G. Dijkstra4, A. van der Meulen - de Jong5, B. Oldenburg6, N. de Boer7, C. Ponsioen8, A. de Vries3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

1Radboudumc, Nijmegen, The Netherlands, 2Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 3Erasmus Medical Center, Rotterdam, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands, 5Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, 6University Medical Centre Utrecht, Utrecht, The Netherlands, 7VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, The Netherlands, 8Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 9Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands